Cureous Labs, an innovative medical technology startup dedicated to enhancing patient care and nursing efficiency, has raised ₹1.66 crore in a Seed funding round. Inflection Point Ventures (IPV) led the investment, with participation from Anthill Ventures.
Funding to Accelerate Manufacturing and Expansion
The startup will use the funds to manufacture its first batch of flagship automated patient repositioning systems, Eturnal™, and build inventory. It will also scale commercial operations through strategic hiring in sales and business development, launch its first disinfection centre, and carry out product safety testing and certifications. Additionally, Cureous Labs plans to expand its product portfolio for B2B customers across India.
Leadership with Proven Healthcare Innovation
Founder and CEO Asish Mohandas brings a strong background in healthcare innovation and user-centered design. A Biodesign Fellow from the prestigious School of International Biodesign at AIIMS and IIT Delhi, he also holds a Master of Design from IIT Kanpur. As the first National James Dyson Awardee for a medical device, Asish has consistently demonstrated expertise. He has developed impactful medical technologies for the Indian healthcare landscape.
Investors Back Vision for Preventive Care
Vinay Bansal, Founder of IPV, explained, “What drew us to invest in Cureous Labs is their commitment to the ‘Prevention is better than Cure’ idea. Around the world, several bedridden patients suffer from pressure injuries, adding to existing ailments. Caregivers face strain and risk while tending to these patients. Cureous Labs has leveraged technology to ease this burden and make prevention more affordable and accessible globally.”
India’s First Retrofittable Automatic Patient Repositioning System
Cureous Labs has developed India’s first retrofittable automatic patient repositioning system with advanced pressure relief. Designed to prevent bedsores and reduce caregiver injuries, Eturnal™ is priced at just one-fifth of international alternatives, making it accessible and cost-effective. The solution is the result of over two years of intensive clinical research and insights gathered from more than 100 hospitals in India and Australia.
Proven Real-World Impact
The startup’s devices are already in use across hospitals, rehabilitation centres, and home care settings. They have logged over 30,000 hours of usage and more than 14,000 automated patient turns. The technology has demonstrated both credibility and impact. Cureous Labs is currently running active B2B and B2C sales and rental pilots across South India.
Mission to Empower Independent Living
“Asish Mohandas stated, “At Cureous, our mission is to create technologies that empower independent living. Eturnal™, our unique automated patient turning solution, prevents pressure injuries while reducing caregiver dependency and effort. We aim to build a portfolio of solutions for geriatric and long-term care. IPV’s early belief in our vision gives us the confidence and resources to scale Cureous into a category-defining company in this space.”
Growing Market Potential for Elderly Care Solutions
As per the press release, the global market for pressure injury prevention and patient care is vast, with over 1.1 billion people aged above 60 and 140 million over the age of 80. Around 154 million people worldwide are bedridden and at risk of developing pressure injuries, contributing to a global market valued at $277 billion. In India, the Total Addressable Market (TAM) is $8.34 billion. The Serviceable Available Market (SAM) is $1.56 billion, and the Serviceable Obtainable Market (SOM) is $656 million. This indicates significant potential for scalable impact and growth.